- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- AZN
- Stock Information
- Founded
- NVS 1895
- AZN 1992
- Country
- NVS Switzerland
- AZN United Kingdom
- Employees
- NVS N/A
- AZN N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- AZN Health Care
- Exchange
- NVS Nasdaq
- AZN Nasdaq
- Market Cap
- NVS 230.5B
- AZN 234.5B
- IPO Year
- NVS 1991
- AZN 1993
- Fundamental
- Price
- NVS $103.41
- AZN $63.82
- Analyst Decision
- NVS Hold
- AZN Buy
- Analyst Count
- NVS 6
- AZN 10
- Target Price
- NVS $121.25
- AZN $88.80
- AVG Volume (30 Days)
- NVS 1.4M
- AZN 8.0M
- Earning Date
- NVS 10-29-2024
- AZN 11-12-2024
- Dividend Yield
- NVS 3.67%
- AZN 2.35%
- EPS Growth
- NVS 130.53
- AZN 9.79
- EPS
- NVS 8.58
- AZN 4.15
- Revenue
- NVS $49,940,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- NVS $10.04
- AZN $17.69
- Revenue Next Year
- NVS $4.55
- AZN $7.95
- P/E Ratio
- NVS $11.67
- AZN $30.32
- Revenue Growth
- NVS 8.92
- AZN 13.81
- 52 Week Low
- NVS $92.35
- AZN $60.47
- 52 Week High
- NVS $120.92
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- NVS 27.27
- AZN 25.83
- Support Level
- NVS $102.40
- AZN $62.88
- Resistance Level
- NVS $103.42
- AZN $64.13
- Average True Range (ATR)
- NVS 0.89
- AZN 1.28
- MACD
- NVS -0.19
- AZN -0.01
- Stochastic Oscillator
- NVS 11.89
- AZN 9.06
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.